Nontuberculous mycobacteria (NTM) is a chronic, progressive illness fraught with long treatments and severe side effects.

The goal of this activity is to improve recognition and differential diagnosis of ILD subtypes at risk of chronic fibrosis, and to improve management of these patients through integration of traditional and newer therapy options into routine practice.

Oncology clinicians would benefit from this educational activity through updates on a multidisciplinary approach to optimally managing patients with pancreatic cancer, with a focus on the efficacy and safety data of current guideline-recommended regimens as well as information on emerging therapies.

Discuss the symptoms of atopic dermatitis that impact patient quality of life

Assess the radiological and histopathological patterns of fibrosis in chronic fibrosing ILDs and their role in defining disease etiology and subsequent management.

Outline cardiovascular risk stratification strategies to effectively screen patients with T2D

Integrate new information about the natural history of IPF and other ILDs into clinical decision-making and discussions with patients about their prognosis.

A deadly disease in children became more treatable. Advancement in therapy demands early diagnosis. Early symptoms should be recognized in primary care practice